New guidelines and recent trials position SGLT2 inhibitors such as dapagliflozin, empagliflozin, and canagliflozin as crucial for slowing chronic kidney disease progression, including in patients without diabetes, with safety considerations and lifestyle factors emphasised.
SGLT2 inhibitors have moved from being mainly diabetes medicines to becoming a central part of kidney protection. The class includes drugs such as dapagliflozin, marketed as Farxiga, empagliflozin, sold as Jardiance, and canagliflozin, known as Invokana. According to the National Kidney Foundation and the Cleveland Clinic, these medicines help the kidneys excrete more glucose and sodium, which lowers blood sugar while also easing pressure inside the kidney’s filtering system.
That broader kidney benefit is why major kidney organisations now recommend them for many adults with chronic kidney disease, including people who do not have diabetes. The article on Plant Powered Kidneys says international guidelines support starting an SGLT2 inhibitor once chronic kidney disease is identified and eGFR is at least 20, and it notes that the 2024 KDIGO update extended this approach to adults with chronic kidney disease regardless of diabetes status. The same article adds that the strongest evidence is in patients with albuminuria, falling eGFR or heart failure.
The evidence base behind that guidance comes from large trials. Plant Powered Kidneys says CREDENCE showed canagliflozin reduced the risk of end-stage kidney disease in people with type 2 diabetes and significant protein in the urine, while DAPA-CKD found dapagliflozin lowered the risk of major kidney decline, end-stage kidney disease or death from kidney or heart causes in people with and without diabetes. It also says EMPA-KIDNEY showed empagliflozin reduced kidney disease progression or heart-related death and appeared to help even in people with little or no protein in the urine.
The practical message for patients is that these drugs are usually started earlier than many expect. The article explains that an eGFR below 30 is often a point for nephrology referral and long-term planning, not a signal to wait before beginning kidney-protective treatment. It also says a small early dip in eGFR is expected after starting therapy and is usually part of the medicine’s effect, not a reason to stop. The National Kidney Foundation and Cleveland Clinic similarly describe SGLT2 inhibitors as medicines that can slow chronic kidney disease progression and lower the risk of heart failure-related complications.
There are, however, important safety considerations. According to the article, the most common side effects are genital yeast infections and urinary tract infections, with dehydration another concern. It says the medicines should be paused during prolonged fasting, major illness or surgery because of the risk of ketosis, a dangerous build-up of acids when the body burns fat for fuel. The article also advises caution with very low-carbohydrate diets, intermittent fasting and other situations that reduce food intake or fluid balance.
Diet still matters. Plant Powered Kidneys argues that SGLT2 inhibitors work best alongside a kidney-friendly eating pattern built around vegetables, fruit, whole grains, beans, fibre, nuts and plant-based proteins, with less processed meat, refined carbohydrate and sugary drinks. It recommends regular balanced meals, enough carbohydrate to avoid unnecessary ketosis risk, hydration within any prescribed fluid limit, and enough calories and protein to protect muscle. For many readers, the key takeaway is that these medicines are not replacements for healthy eating or other kidney-protective drugs, but part of a broader treatment plan.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
